Literature DB >> 14503023

Hypertension, hypertension-clustering factors and Alzheimer's disease.

Ingmar Skoog1, Deborah Gustafson.   

Abstract

Hypertension is a risk factor for stroke, ischemic white matter lesions, silent infarcts, general atherosclerosis, myocardial infarction and cardiovascular morbidity and mortality. This risk increases with increasing blood pressure also at blood pressure within the normal ranges, and a high percentage of these cardiovascular events occur in those with normal blood or mild hypertension. Several studies have reported that high blood pressure precedes Alzheimer's disease by decades, but blood pressure decreases the years before dementia onset and is lower in individuals with Alzheimer's disease than in controls. High blood pressure has also been related to the neuropathological manifestations of Alzheimer's disease. Hypertension often clusters with other vascular risk factors, including diabetes mellitus, obesity, and hypercholesterolemia. Also, these risk factors have been related to Alzheimer's disease. The exact mechanism behind these associations is not clear. Hypertension may cause cerebrovascular disease that may increase the likelihood that individuals with AD encephalopathy will express a dementia syndrome, but hypertension may also accelerate the AD process, subclinical AD may lead to increased blood pressure, and similar biological mechanisms may be involved in the pathogenesis of both disorders. Hypertension is a common disorder and often untreated. Even if hypertension only results in a moderately increased risk of AD, or overall dementia, better treatment of hypertension may have an immense effect on the total numbr of demented individuals.

Entities:  

Mesh:

Year:  2003        PMID: 14503023     DOI: 10.1179/016164103101201986

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  27 in total

1.  The benefits of apolipoprotein E epsilon4 screening to research.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

Review 2.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

3.  The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics.

Authors:  Michal Schnaider Beeri; Ramit Ravona-Springer; Erin Moshier; James Schmeidler; James Godbold; Tomas Karpati; Derek Leroith; Keren Koifman; Efrat Kravitz; Rachel Price; Hadas Hoffman; Jeremy M Silverman; Anthony Heymann
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

4.  Nontraditional risk factors combine to predict Alzheimer disease and dementia.

Authors:  Xiaowei Song; Arnold Mitnitski; Kenneth Rockwood
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

5.  Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers.

Authors:  M S Beeri; M Rapp; J M Silverman; J Schmeidler; H T Grossman; J T Fallon; D P Purohit; D P Perl; A Siddiqui; G Lesser; C Rosendorff; V Haroutunian
Journal:  Neurology       Date:  2006-05-09       Impact factor: 9.910

6.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

7.  Antihypertensive medication is associated with less cognitive impairment in the very old with apolipoprotein-E epsilon4 allele.

Authors:  Knut A Hestad; Knut Engedal
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

8.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

Review 9.  The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease.

Authors:  Chao-Liang Chou; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.